An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers

Cell Death Discovery

Volumn 2, Issue 1, 2016, Pages

  Tang, H M ^a   Kuay, K T ^a   Koh, P F ^a   Asad, M ^b   Tan, T Z ^a   Chung, V Y ^a   Lee, S C ^a,b   Thiery, J P ^a,c,d,e   Huang, Ry J ^a,b,f  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ PARIS DIDEROT   (France)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85069157892     PISSN: None     EISSN: 20587716     Source Type: Journal    
DOI: 10.1038/cddiscovery.2016.41     Document Type: Article

References (48)

1. Huang RY, Chung VY, Thiery JP. Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer. Curr Drug Targets 2012; 13: 1649–1653.
2. Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal transition plasticity in cancer. Nat Med 2013; 19: 1438–1449.
3. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871–890.
4. Marcucci F, Stassi G, De Maria R. Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discov 2016; 15: 311–325.
5. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15: 178–196.
6. Chua KN, Poon KL, Lim J, Sim WJ, Huang RY, Thiery JP. Target cell movement in tumor and cardiovascular diseases based on the epithelial-mesenchymal transition concept. Adv Drug Deliv Rev 2011; 63: 558–567.
7. Lacher MD, Tiirikainen MI, Saunier EF, Christian C, Anders M et al. Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res 2006; 66: 1648–1657.
8. Huang RY, Wong MK, Tan TZ, Kuay KT, Ng AHC, Chung VY et al. An EMT spectrum defines an an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death and Dis 2013; 4: e915.
9. Huang RY, Kuay KT, Tan TZ, Mohammad A, Tang HM, Ng AHC et al. Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120). Oncotarget 2015; 6: 22098–22113.
10. Rangarajan S, Kurundkar A, Kurundkar D, Bernard K, Sanders YY, Ding Q et al. Novel mechanisms for the anti-fibrotic action of nintedanib. Am J Respir Cell Mol Biol 2015; 54: 51–59.
11. Beug H. Breast cancer stem cells: eradication by differentiation therapy? Cell 2009; 138: 623–625.
12. Sell S, Nicolini A, Ferrari P, Biava PM. Cancer: a problem of developmental biology; scientific evidence for reprogramming and differentiation therapy. Curr Drug Targets 2015; 16: 1–8.
13. Johnson DE, Redner RL. An ATRActive future for differentiation therapy in AML. Blood Rev 2015; 29: 263–268.
14. Morceau F, Chaleauvieux S, Orsini M, Trecul A, Dicato M, Diederich M. Natural compounds and pharmaceuticals reprogram leukemia cell differentiation pathways. Biotechnol Adv 2015; 33: 785–797.
15. Cruz FD, Matushansky I. Solid tumour differentiation therapy- is it possible? Oncotarget 2012; 3: 559–567.
16. Azzi S, Bruno S, Giron-Michel J, Clay D, Devocelle A, Croce M et al. Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. J Natl Cancer Inst 2011; 103: 1884–1898.
17. Shukla S, Meeran SM. Epigenetics of cancer stem cells: pathways and therapeutics. Biochem Biophys Acta 2014; 1840: 3494–3502.
18. Luo M, Brooks M, Wicha MS. Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance. Curr Pharm Des 2015; 21: 1301–1310.
19. Tan TZ, Miow QH, Miki Y, Noda T, Mori S et al. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med 2014; 6: 1279–1293.
20. Wang J, Pursell NW, Samson ME, Atoyan R, Ma AW, Selmi A et al. Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion. Mol Cancer Ther 2013; 12: 925–936.
21. Zhang L, Zhang Y, Mehta A, Boufragech M, Davis S, Wang J et al. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. Oncotarget 2015; 6: 9073–9085.
22. Chung VY, Tan TZ, Tan M, Wong MK, Kuay KT, Yang Z et al. GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification. Sci Rep 2016; 6: 19943.
23. Cieply B, Riley P 4th, Pifer PM, Widmeyer J, Addison JB, Ivanov AV et al. Suppression of the epithelial-mesenchymal transition by Grainyhead-like-2. Cancer Res 2012; 72: 2440–2453.
24. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 2007; 16: 659–678.
25. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12: 1247–1252.
26. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 2007; 13: 2318–2322.
27. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27: 5410–5417.
28. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011; 117: 5827–5834.
29. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005; 23: 3912–3922.
30. Gore L, Rothenberg ML, O'Bryant CL, Schultz MK, Sandler AB, Coffin D et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 2008; 14: 4517–4525.
31. Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S et al. Mocetinostat for relapsed classical Hodgkin’s lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011; 12: 1222–1228.
32. Ocker M, Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 2007; 39: 1367–1374.
33. Ocker M. Deacetylase inhibitors - focus on non-histone targets and effects. World J Biol Chem 2010; 1: 55–61.
34. Kong D, Ahmad A, Bao B, Li YW, Banerjee B, Sarkar FH. Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. PLoS One 2012; 7: e45045.
35. Jiang GM, Wang HS, Zhang F, Zhang KS, Liu ZC, Fang R et al. Histone deacetylase inhibitor induction of epithelial–mesenchymal transitions via up-regulation of Snail facilitates cancer progression. Biochim Biophys Acta 2013; 1833: 663–671.
36. Chikamatsu K, Ishii H, Murata T, Sakakura K, Shino M, Toyoda M et al. Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck. Cancer Sci 2013; 104: 1468–1475.
37. Liao W, Jordaan G, Srivastava MK, Dubinett S, Sharma S, Sharma S. Effect of epigenetic histone modifications on E-cadherin splicing and expression in lung cancer. Am J Cancer Res 2013; 3: 374–389.
38. Rhodes LV, Tate CR, Segar HC, Burks HE, Phamduy TB, Hoang V et al. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res Treat 2014; 145: 593–604.
39. Meidhof S, Brabletz S, Lehman W, Preca BT, Mock K, Ruh M et al. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Med 2015; 7: 831–847.
40. Schech A, Kazi A, Yu S, Shah P, Sabnis G. Histone deacetylase inhibitor entinostat inhibits tumor-initiating cells in triple-negative breast cancer cells. Mol Cancer Ther 2015; 14: 1848–1857.
41. Miow QH, Tan TZ, Ye J, Lau JA, Yokomizo T, Thiery JP et al. Epithelial–mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene 2015; 34: 1899–1907.
42. El-Kenawi AE, Cowell JK. Effects of cisplatin, vorinostat, and their combinations on EGFR-overexpressing cell lines. Cancer Res 2014; 74(19 Suppl): Abstract 4560.
43. Peinado H, Ballestar E, Esteller M, Cano A. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol 2004; 24: 306–319.
44. von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 2009; 137: 361–371.
45. Wu MZ, Tsai YP, Yang MH, Huang CH, Chang SY, Chang CC et al. Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. Mol Cell 2011; 43: 811–822.
46. Gaborit N, Lindzen M, Yarden Y. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Hum Vaccin Immunother 2015; 12: 576–592.
47. Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 2011; 226: 2378–2390.
48. Ciardiello C, Roca MS, Noto A, Bruzzese F, Moccia T, Vitagliano C et al. Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression. Oncotarget 2016; e-pub ahead of print 4 February 201610.18632/oncotarget.7195.